General Atlantic’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,354,830
| Closed | -$53.8M | – | 13 |
|
|
2026
Q1 | $53.8M | Sell |
1,354,830
-4,762,885
| -78% | -$122M | 2.5% | 9 |
|
|
2025
Q4 | $153M | Sell |
6,117,715
-3,564,103
| -37% | -$90.3M | 5.33% | 8 |
|
|
2025
Q3 | $235M | Hold |
9,681,818
| – | – | 7.05% | 7 |
|
|
2025
Q2 | $127M | Hold |
9,681,818
| – | – | 3.51% | 8 |
|
|
2025
Q1 | $139M | Hold |
9,681,818
| – | – | 4.67% | 6 |
|
|
2024
Q4 | $162M | Hold |
9,681,818
| – | – | 5.77% | 5 |
|
|
2024
Q3 | $155M | Hold |
9,681,818
| – | – | 4.4% | 6 |
|
|
2024
Q2 | $87.4M | Hold |
9,681,818
| – | – | 2.75% | 9 |
|
|
2024
Q1 | $109M | Hold |
9,681,818
| – | – | 2.54% | 10 |
|
|
2023
Q4 | $77.1M | Hold |
9,681,818
| – | – | 1.11% | 11 |
|
|
2023
Q3 | $62.6M | Hold |
9,681,818
| – | – | 0.97% | 17 |
|
|
2023
Q2 | $59.9M | Hold |
9,681,818
| – | – | 0.94% | 16 |
|
|
2023
Q1 | $37.3M | Hold |
9,681,818
| – | – | 0.43% | 21 |
|
|
2022
Q4 | $30M | Hold |
9,681,818
| – | – | 0.4% | 22 |
|
|
2022
Q3 | $38.9M | Hold |
9,681,818
| – | – | 0.46% | 19 |
|
|
2022
Q2 | $47.1M | Hold |
9,681,818
| – | – | 0.62% | 18 |
|
|
2022
Q1 | $86.8M | Hold |
9,681,818
| – | – | 0.79% | 12 |
|
|
2021
Q4 | $109M | Hold |
9,681,818
| – | – | 0.84% | 14 |
|
|
2021
Q3 | $162M | Buy |
9,681,818
+8,181,818
| +545% | +$169M | 0.95% | 12 |
|
|
2021
Q2 | $33.3M | Buy |
+1,500,000
| New | +$35.3M | 0.24% | 14 |
|
General Atlantic's CNTA Position: Q2 2026 in Review
General Atlantic sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 1,354,830 shares — an estimated $53.8M sold.
General Atlantic first reported a position in CNTA in Q2 2021 and held it in 20 quarters. The position peaked at $235M in Q3 2025. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- General Atlantic reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- General Atlantic sold 1,354,830 Centessa Pharmaceuticals shares in Q2 2026, an estimated $53.8M.
- General Atlantic first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 20 quarters.
- General Atlantic's Centessa Pharmaceuticals position peaked at $235M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on General Atlantic's 13F filing for Q2 2026, filed 14 Aug 2026.